Notice to Our Patients Regarding a Stolen Briefcase. Learn More
Clinical Trials Search
A Phase 1, Multi-center, Open-label, Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of an Orally Available Small Molecule CC-99282 Alone and in Combination with Rituximab in Subjects with Relapsed and/or Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) and Indolent Non-Hodgkin Lymphoma (R/R iNHL)
The purpose of this study is to test the safety of the new experimental drug, CC-99282. For some participants with DLBCL or FL enrolling in Part B of the study, an additional purpose is to test the safety of CC-99282 in combination with rituximab.
Primary Objectives: To determine the safety and tolerability of CC-99282 alone and in combination with rituximab in subjects with R/R NHL. To define the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of CC-99282 in subjects with R/R NHL. Secondary Objectives: To characterize the pharmacokinetics (PK) of CC-99282. To provide information on the preliminary efficacy of CC-99282 alone and in combination with rituximab in R/R NHL.
CC-99282 (); Rituxan (rituximab); rituximab ()